reports
Hemostemix Inc: 1 director
A director at Hemostemix Inc sold 1,812,500 shares at 0.069CAD and the significance rating of the trade was 71/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearl...
- Sid Rajeev
SYH SKYHARBOUR RESOURCES LTD.
RFR RENFORTH RESOURCES INC.
RKS ROCKSHIELD CAPITAL
WRP WESTERN PACIFIC RESOURCES CORP.
HEM. HEMOSTEMIX
HAN HANNAN METALS LTD
LMR LOMIKO METALS INC
LUM LUMINA GOLD CORP
GRC GOLD SPRINGS RESOURCE
KIDZ KIDOZ
BIGG BIGG DIGITAL ASSET
ROVR ROVER METALS CORP.
SWIS SEKUR PRIVATE DATA LTD.
- Sid Rajeev
PML. PANORO MINERALS LTD.
WRP WESTERN PACIFIC RESOURCES CORP.
WRM WHITE ROCK MINERALS
NAM NEW AGE METALS
ECR. CARTIER RESOURCES
HEM. HEMOSTEMIX
LMR LOMIKO METALS INC
NRTH 48NORTH CANNABIS CORP.
AMY AMERICAN MANGANESE INC.
CBI COLIBRI RESOURCE CORPORATION
MQR MONARCH MINING CORPORATION
BIGG BIGG DIGITAL ASSET
TAAT TAAT GLOBAL ALTERNATIVES INC.
ATLY ALTALEY MINING CORPORATION
SIC SOKOMAN MINERALS CORP
- Sid Rajeev
Hemostemix Announces Grant of Stock Options
Calgary, Alberta--(Newsfile Corp. - January 4, 2021) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) ("Hemostemix" or the "Company") announces that, in accordance with its stock option plan, it has granted on December 31, 2020, subject to regulatory approval, a total of 5,274,500 stock options to purchase common shares of Hemostemix (the "Options") to directors, officers, employees and consultants of Hemostemix. Of the Options granted 3,887,100 vest immediately and 1,387,400 vest 50% immediately and 50% on December, 31 2021. All options were granted with an exercise price of $0.70 per common share...
Hemostemix Announces Closing of Unit Private Placement
Calgary, Alberta--(Newsfile Corp. - December 31, 2020) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) ("Hemostemix" or the "Company") announces it has closed its previously announced non-brokered private placement of units ("Units") announced on December 18, 2020, for gross proceeds of $2,750,000 (the "Offering"). The Offering consisted of the issuance of an aggregate of 9,166,667 post -consolidated Units at a price of $0.30 per Unit. Each Unit consists of one post-consolidated common share in the capital of the Company ("Common Share") and one post-consolidated common share purchase warrant ("...
Hemostemix Announces Private Placement Update
Calgary, Alberta--(Newsfile Corp. - December 29, 2020) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) ("Hemostemix" or the "Company") announces that it was granted price protection of its previously announced non-brokered private placement of units ("Units") announced on December 18, 2020, for gross proceeds of up to $2,750,000 (the "Offering"). The Offering will consist of the issuance of an aggregate of up to 9,166,666 post rollback Units at a price of $0.30 per Unit. Each Unit consists of one post rollback common share in the capital of the Company ("Common Share") and one post rollback comm...
Hemostemix Announces Corporate Update
Calgary, Alberta--(Newsfile Corp. - December 23, 2020) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) ("Hemostemix" or the "Company") The Company is pleased to announce that the previously disclosed proposed consolidation of the common shares of the Company on the basis of twenty pre-consolidation shares for one post-consolidation share (the "Consolidation") will take effect, subject to final acceptance by the TSX Venture Exchange, on or about December 30, 2020 under new CUSIP number 423694306. There will be no name change or trading symbol change in conjunction with the Consolidation. The Consol...
Hemostemix Announces Closing of Existing Private Placement and Announc...
Calgary, Alberta--(Newsfile Corp. - December 18, 2020) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) ("Hemostemix" or the "Company") announces it has closed its previously announced non-brokered private placement of units ("Units") for gross proceeds of $1,272,117.04 (the "Offering"). The Offering consisted of the issuance of an aggregate of 127,211,704 Units at a price of $0.01 per Unit. Each Unit consists of one common share in the capital of the Company ("Common Share") and one common share purchase warrant ("Warrant"), with each full Warrant entitling the holder to acquire one Common Share ...
Hemostemix Files Its Unaudited Condensed Consolidated Interim Financia...
Calgary, Alberta--(Newsfile Corp. - July 13, 2020) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) ("Hemostemix" or the "Company") today filed on SEDAR its unaudited Condensed Consolidated Interim Financial Statements and Management Discussion and Analysis for the quarter ending March 31, 2020 and for the comparable period ending March 31, 2019.ABOUT HEMOSTEMIX Hemostemix is a publicly traded autologous stem cell therapy company. A winner of the World Economic Forum Technology Pioneer Award, the Company developed and is commercializing its lead product ACP-01 for the treatment of CLI, PAD, Angina, ...
Hemostemix Files Its Audited Annual Financial Statements and Managemen...
Calgary, Alberta--(Newsfile Corp. - July 10, 2020) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) ("Hemostemix" or the "Company") today filed on SEDAR its audited Financial Statements and Management Discussion and Analysis for the annual period and fourth quarter ending December 31, 2019 and for the comparable periods ending December 31, 2018.ABOUT HEMOSTEMIX Hemostemix is a publicly traded autologous stem cell therapy company. A winner of the World Economic Forum Technology Pioneer Award, the Company developed and is commercializing its lead product ACP-01 for the treatment of CLI, PAD, Angina, I...
Hemostemix Announces Closing of Private Placement
Calgary, Alberta--(Newsfile Corp. - July 9, 2020) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) ("Hemostemix" or the "Company") announces it has closed its previously announced non-brokered private placement of units ("Units") for gross proceeds of $266,500(the "Offering"). The Offering consisted of the issuance of an aggregate of 26,650,000 Units at a price of $0.01 per Unit. Each Unit consists of one common share in the capital of the Company ("Common Share") and one common share purchase warrant ("Warrant"), with each full Warrant entitling the holder to acquire one Common Share at a price of...
Delaware Court Grants An Order for the Expedited Briefing Schedule of ...
Calgary, Alberta--(Newsfile Corp. - July 6, 2020) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) ("Hemostemix" or the "Company") is pleased to announce that the United States District Court for the District of Delaware has granted an order for the expedited briefing schedule on Hemostemix's Injunction application seeking the immediate return of all clinical trial data from Accudata Solutions, Inc. ("Accudata"). The Order directs Defendant Accudata to file an Answering Brief in response to Hemostemix's Motion for Preliminary Injunction on or before July 9, 2020. The Hemostemix Reply Brief in suppor...
Hemostemix Filed an Injunction Against Accudata Solutions, Inc. for th...
Calgary, Alberta--(Newsfile Corp. - July 3, 2020) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) ("Hemostemix" or the "Company") is pleased to announce on June 29, 2020, it filed a Verified Complaint and, on July 2, 2020, Motions for a Preliminary Injunction and Expedited Scheduling seeking to compel the immediate return of all clinical trial data from Defendant Accudata Solutions, Inc. ("Accudata") and enjoining Accudata from continuing to divulge and disclose such highly sensitive and confidential information to third parties who have no ownership or custodial right to it.Hemostemix engaged the ...
Hemostemix Appeals Alberta Court's Service Ex Juris Decision
Calgary, Alberta--(Newsfile Corp. - June 24, 2020) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) ("Hemostemix" or the "Company") announces that, further to its June 19, 2020 news release, Hemostemix has filed a fast track appeal in relation to the Alberta Court of Queen's Bench erroneous service ex juris decision rendered on June 18, 2020 in relation to Hemostemix's Replevin application seeking access to and a copy of Hemostemix's own property which is being wrongfully withheld from Hemostemix by Aspire Health Science, LLC. In addition, Hemostemix announces that on June 19, 2020, the Court issued...
Hemostemix Announces $700,000 Non Broker Private Placement, Update on ...
Calgary, Alberta--(Newsfile Corp. - June 19, 2020) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) ("Hemostemix" or the "Company") is pleased to announce a non-brokered private placement of units ("Units") for gross proceeds of up to $700,000 (the "Offering"), subject to TSX Venture Exchange (the "Exchange") approval. The Offering may consist of the issuance of an aggregate of 70,000,000 Units at a price of $0.01 per Unit. Each Unit consists of one Common Share in the capital of the Company ("Common Share") and one Common Share purchase warrant ("Warrant"), with each full Warrant entitling the hol...
Hemostemix Announces Delay in Filing of Annual Financial Statements an...
Calgary, Alberta--(Newsfile Corp. - June 16, 2020) - Hemostemix Inc. ("Hemostemix" or the "Company") (TSXV: HEM) (OTC: HMTXF) announces, that it has not met the revised filing date, as provided in Alberta Blanket Order 51-517 Temporary Exemption from Certain Corporate Finance Requirements (the "Alberta Order") of the Alberta Securities Commission (and similar exemptions provided by the securities commission in British Columbia) of June 15, 2020, for filing of the following continuous disclosure documents (collectively, the "Documents"):the Company's Annual Audited Financial Statements fo...
Hemostemix Announces Aspire Health Science, LLC Has No Right to Manufa...
Calgary, Alberta--(Newsfile Corp. - June 8, 2020) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) ("Hemostemix" or the "Company") is pleased to announce that ownership and control of its intellectual property is an uncontested fact, and the Company is in communication with each clinical trial site. The Company has lawfully and properly cancelled certain license rights to Aspire Health Science, LLC ("Aspire")."Hemostemix's intellectual property is uncontested," said Thomas Smeenk, CEO. "We reserve our rights to all damages against any individuals and all parties who manufacture or distribute ACP-01...
Hemostemix Announces Dr. Mary Argent-Katwala as Its Clinical Trial Man...
Calgary, Alberta--(Newsfile Corp. - June 3, 2020) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) ("Hemostemix" or the "Company") is pleased to announce the appointment of Dr. Mary Argent-Katwala to the position of Manager, Clinical Trials.Dr. Argent-Katwala earned her PhD in molecular biology from the Institute of Cancer Research, University of London, UK and her MA (Hons.), Biological Sciences at Newnham College, University of Cambridge, UK. Previously, Dr. Argent-Katwala was Director, Diagnosis & Clinical Care at the Canadian Partnership Against Cancer, Toronto, ON where she created a portfolio ...
Hemostemix Announces Injunction Hearing Against Aspire Health Science,...
Calgary, Alberta--(Newsfile Corp. - June 3, 2020) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) ("Hemostemix" or the "Company") is pleased to announce that it has retained DLA Piper, a global law firm, and filed for an injunction against Aspire Health Science, LLC, for the return of the Company's property. A hearing for the injunction is set for June 18, 2020 at 10:00 MDT before the Court of Queen's Bench, Alberta. Equally, the Company is pleased to announce DLA Piper filed an amended motion to dismiss the Aspire Health Science, LLC Complaint in the Complex Business Litigation Court of the Ninth...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.